This menu provides the list of EV miRNAs identified by high-throughput analyses.
Refresh all contents
Search:
Dataset accession
miRBase accession
Mature name
Orthologous group
Superdomain:
All
Prokaryote
Eukaryote
Filter datasets:
- "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
- "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
By species
Homo sapiens
In vitro/In vivo
Ex vivo
In vitro
In vivo
By sample type
Adult fibroblast
Blood
Bone marrow CD34+ cells
Bone marrow-derived mesenchymal stem cell (R14)
Gastric cancer cells (SGC-7901)
Liver cancer cells (CSQT-2)
Liver cancer cells (HCC-LM3)
Liver cancer cells (HepG2)
Liver cancer cells (MHCC-97L)
Lung cancer cells (A549)
Mast cell (HMC-1)
Plasma
Saliva
Serum
By sample status
Acute myeloid leukemia
Cisplatin-resistant
Extremely severe hand, foot, and mouth disease
Healthy_timepoint1
Healthy_timepoint2
High density
Low density
Mild hand, foot, and mouth disease
Multiple sclerosis
Normal
Normal_Agilent
Normal_Exiqon
Omeprazole-treated
Oral lichen planus patient
Pancreatic cancer patient_Agilent
Pollen allergy_timepoint1
Pollen allergy_timepoint2
Maximum false positive rate (FPR):
Maximum true positive rate (TPR):
- FPR is the probability that an absent miRNA accidently have higher intensity than that miRNA.
- TPR is the percentile of miRNA among the present miRNAs.
Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:
100
200
All
The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.
Since there are multiple primers in the microarray, the same miRNA can have several FPR and TPR values.
Mature name
miRBase accession
FPR
TPR
Publication
Orthologous group
Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
1.2e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
1.3e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
3.8e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
3.9e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
9.3e-2
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
7.9e-2
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
9.1e-2
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
2.5e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
2.6e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
4.8e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
5.0e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
3.6e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
4.5e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
4.3e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
4.4e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
4.8e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
5.0e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
2.1e-2
2.1e-2
Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis.
Nat Commun. 2018 Jan 2;9(1):17. doi: 10.1038/s41467-017-02406-2.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
1.2e-2
1.2e-2
Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis.
Nat Commun. 2018 Jan 2;9(1):17. doi: 10.1038/s41467-017-02406-2.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
4.4e-4
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
3.1e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
0.0e+0
5.0e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
0.0e+0
7.9e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
9.3e-4
9.3e-4
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
1.5e-3
1.5e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642a-3p
MIMAT0020924
1.3e-3
1.3e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
hsa-miR-642b-3p
MIMAT0018444
3.1e-3
3.1e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000468_2
28
/
0
/
28
<
[3]